BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 11046080)

  • 1. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
    Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
    J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
    Storey RF; Oldroyd KG; Wilcox RG
    Thromb Haemost; 2001 Mar; 85(3):401-7. PubMed ID: 11307804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.
    Ingall AH; Dixon J; Bailey A; Coombs ME; Cox D; McInally JI; Hunt SF; Kindon ND; Teobald BJ; Willis PA; Humphries RG; Leff P; Clegg JA; Smith JA; Tomlinson W
    J Med Chem; 1999 Jan; 42(2):213-20. PubMed ID: 9925726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of experimental carotid artery thrombosis by applaggin.
    Rote WE; Mu DX; Roncinske RA; Frelinger AL; Lucchesi BR
    J Pharmacol Exp Ther; 1993 Nov; 267(2):809-14. PubMed ID: 8246155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.
    Storey RF; Wilcox RG; Heptinstall S
    Platelets; 2002 Nov; 13(7):407-13. PubMed ID: 12487788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
    Wang K; Zhou X; Zhou Z; Tarakji K; Carneiro M; Penn MS; Murray D; Klein A; Humphries RG; Turner J; Thomas JD; Topol EJ; Lincoff AM
    Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):357-62. PubMed ID: 12588784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
    van Giezen JJ; Humphries RG
    Semin Thromb Hemost; 2005 Apr; 31(2):195-204. PubMed ID: 15852223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
    Goto S; Tamura N; Ishida H; Ruggeri ZM
    J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
    Behan MW; Fox SC; Heptinstall S; Storey RF
    Platelets; 2005 Mar; 16(2):73-80. PubMed ID: 15823862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The P2Y12 receptor as a therapeutic target in cardiovascular disease.
    Storey RF
    Platelets; 2001 Jun; 12(4):197-209. PubMed ID: 11454254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
    Johnson FL; Boyer JL; Leese PT; Crean C; Krishnamoorthy R; Durham T; Fox AW; Kellerman DJ
    Platelets; 2007 Aug; 18(5):346-56. PubMed ID: 17654304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
    Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
    Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
    Storey RF; Judge HM; Wilcox RG; Heptinstall S
    Thromb Haemost; 2002 Sep; 88(3):488-94. PubMed ID: 12353080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability.
    van Gestel MA; Heemskerk JW; Slaaf DW; Heijnen VV; Reneman RS; oude Egbrink MG
    Arterioscler Thromb Vasc Biol; 2003 Mar; 23(3):518-23. PubMed ID: 12615691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus.
    Shebuski RJ; Ramjit DR; Sitko GR; Lumma PK; Garsky VM
    Thromb Haemost; 1990 Dec; 64(4):576-81. PubMed ID: 2084943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
    Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
    Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.